25.30
+1.65%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Guangdong Zhongsheng Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 002317.SZ. It has been listed since 11 December 2009. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.52bn and net income of CN¥275.8m. At that date it held total assets of CN¥5.13bn and shareholders' equity of CN¥4.06bn.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. engages in the manufacture, sale, research and development of medicine. The company is headquartered in Dongguan, Guangdong. The company went IPO on 2009-12-11. is a China-based company principally engaged in the research, development, manufacture and distribution of medicines. The Company’s medicine products are categorized into Chinese patent medicines, chemical drugs, chemical bulk drugs and herbal decoction pieces, which include capsules for thrombus, pellets for upper respiratory tract diseases, granular for sunstroke, compound dexamethasone acetate creams and azelastine hydrochloride eye drops, among others. The firm distributes its products in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 11 Dec 2009
- Employees
- 1,637
- Website
- zspcl.com ↗
Leadership
Pay as last reported
- Mr. Yonghong ChenChairman of the Board, PresidentCN¥513,500
- Ms. Yuchong ZhangVice Chairman of the Board, Senior Vice President, since 2016CN¥331,200
- Ms. Chunhua LongChief Financial Officer, Vice President, Director, since 2010CN¥376,100
- Mr. Shuang LiuVice PresidentCN¥552,400
- Mr. Rikang LuoVice President
- Mr. Wei YangSecretary of the BoardCN¥579,900
- Mr. Peng'an ShanDirectorCN¥72,000
- Mr. Wen TanDirectorCN¥72,000
- Mr. Xiping ZhaoDirector, since 2010CN¥373,000
- Mr. Ruichao LinIndependent DirectorCN¥72,000
- Ms. Xiaorong MouIndependent DirectorCN¥72,000
- Mr. Qinggong WuIndependent DirectorCN¥72,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 42
- Environment
- 29
- Social
- 21
- Governance
- 75
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Dongguan, Guangdong with 1,637 employees.
- Engages in manufacturing, sales, R&D of medicines including Chinese patent medicines and chemical drugs.
- Distributes products domestically in China.
Weaknesses
- No international market presence mentioned.
- Reliance on domestic market for product distribution.
- No information on global expansion strategies.
Opportunities
- Potential growth in domestic pharmaceutical market.
- Expansion into international markets for product distribution.
- Opportunities in R&D for new medicine categories.
Threats
- Dependence on domestic market may limit growth.
- Competition from other pharmaceutical companies in China.
- Lack of information on global market threats.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.